[Munhwa News | Reporter Sunhye Park]
REV-MED Co., Ltd. announced on the 13th that it presented clinical research on the orthopedic treatment efficacy of its product TriCell PRP at TNOACON 2025, held in India from February 7 to 9. The presentation reaffirmed the competitiveness of Korean biomedical technology in the global arena.
TNOACON, hosted annually by the Tamil Nadu Orthopaedic Association, serves as a key academic platform to promote innovation and collaboration in the orthopedic field.
At this year’s event, Dr. Elizabeth Vinod, a key medical advisor for REV-MED, delivered a lecture titled “Clinical Effectiveness of PRP-Based Treatments in Orthopedics.” Her presentation focused on the regenerative and pain-relieving effects of REV-MED’s TriCell PRP technology.
TriCell PRP uses a double-spin technique to achieve a significantly higher platelet concentration than conventional single-spin methods, thereby enhancing therapeutic outcomes. Developed entirely with domestic Korean technology, the device ensures both safety and efficiency, gaining strong trust among medical professionals worldwide.
Globally, PRP technology is gaining prominence in the treatment of tissue regeneration and chronic conditions. It is increasingly recognized as a minimally invasive, effective alternative, especially for sports injuries and degenerative disorders. In this context, TriCell PRP’s unique design and performance continue to position it as a strong contender in the global PRP device market.
A REV-MED representative commented,
“The research presentation at TNOACON 2025 was a valuable opportunity to highlight the strength of our minimally manipulated biologic concentration technology to the global medical community. We will continue to expand our market share both domestically and internationally through ongoing academic engagement and product innovation.”
Meanwhile, in December 2024, the intra-articular injection of autologous PRP for early-stage knee osteoarthritis was officially registered as a new medical technology by the Korean Ministry of Health and Welfare.
Source: Munhwa News
[Munhwa News | Reporter Sunhye Park]
REV-MED Co., Ltd. announced on the 13th that it presented clinical research on the orthopedic treatment efficacy of its product TriCell PRP at TNOACON 2025, held in India from February 7 to 9. The presentation reaffirmed the competitiveness of Korean biomedical technology in the global arena.
TNOACON, hosted annually by the Tamil Nadu Orthopaedic Association, serves as a key academic platform to promote innovation and collaboration in the orthopedic field.
At this year’s event, Dr. Elizabeth Vinod, a key medical advisor for REV-MED, delivered a lecture titled “Clinical Effectiveness of PRP-Based Treatments in Orthopedics.” Her presentation focused on the regenerative and pain-relieving effects of REV-MED’s TriCell PRP technology.
TriCell PRP uses a double-spin technique to achieve a significantly higher platelet concentration than conventional single-spin methods, thereby enhancing therapeutic outcomes. Developed entirely with domestic Korean technology, the device ensures both safety and efficiency, gaining strong trust among medical professionals worldwide.
Globally, PRP technology is gaining prominence in the treatment of tissue regeneration and chronic conditions. It is increasingly recognized as a minimally invasive, effective alternative, especially for sports injuries and degenerative disorders. In this context, TriCell PRP’s unique design and performance continue to position it as a strong contender in the global PRP device market.
A REV-MED representative commented,
“The research presentation at TNOACON 2025 was a valuable opportunity to highlight the strength of our minimally manipulated biologic concentration technology to the global medical community. We will continue to expand our market share both domestically and internationally through ongoing academic engagement and product innovation.”
Meanwhile, in December 2024, the intra-articular injection of autologous PRP for early-stage knee osteoarthritis was officially registered as a new medical technology by the Korean Ministry of Health and Welfare.
Source: Munhwa News